Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This study, which reinforces the importance of repeating a biopsy at relapse before implementing CD20-directed therapy, is particularly relevant given the widespread use of rituximab along with the emerging significance of CD20-targeted bispecific antibodies in the management of B-cell lymphomas.
Authors
- Marcin Dragan
- Sarah Tomassetti (ORCID: https://orcid.org/0000-0001-6087-8788)
- Joseph P. Marshalek (ORCID: https://orcid.org/0000-0002-7362-3909)
- Xin Qing (ORCID: https://orcid.org/0000-0001-8109-590X)
Institutions
- UCLA Medical Center (US)
- Harbor–UCLA Medical Center (US)
Publication Details
- Journal
- Journal of Hematology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.14740/jh1341
- Citations
- 4
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70